CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- 8-K Event Regulation FD disclosure · Other events
- 8-K Event Bylaws or fiscal year change
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Grant or award President and CEO acquired 156,400 shares (grant or award)
- 4 Open-market sale EVP, General Counsel sold 1,211 shares at $13.78 ($16,688)
- 4 Grant or award EVP, Chief Medical Officer acquired 9,943 shares (grant or award)
- 4 Grant or award EVP, Chief Financial Officer acquired 61,280 shares (grant or award)
- 4 Grant or award EVP, Chief Scientific Officer acquired 39,200 shares (grant or award)
- 4 Open-market sale EVP, Chief Technical Officer sold 607 shares at $13.78 ($8,364)
- 4 Grant or award VP, Chief Accounting Officer acquired 17,250 shares (grant or award)
- 424B5 Offering Prospectus
- 8-K Event Material agreement · Regulation FD disclosure · Other events
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
Page 3 of 37 · 725 filings